A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Aspirin (Primary) ; Atezolizumab (Primary) ; Bevacizumab (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 23 Dec 2016 Status changed from not yet recruiting to recruiting.
- 11 Oct 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2021.
- 11 Oct 2016 Planned initiation date changed from 1 May 2016 to 1 Sep 2016.